S. Um

发表

Abstract A49: Circulating tumor cell (CTC) assay development for detection of H2AX as a clinical pharmacodynamic (PD) marker for Chk1 kinase inhibitors.

J. Dempsey, R. Beckmann, M. Marshall, 2011 .

Evaluation of anti‐activated protein C antibody development in patients with severe sepsis from four clinical studies with drotrecogin alfa (activated)

J. Brandt, S. Um, S. Yan, 2009, Journal of thrombosis and haemostasis : JTH.

Abstract 1776: Antitumor activity of Chk1 inhibitor LY2606368 as a single agent in SW1990 human pancreas orthotopic tumor model

Chen Bi, R. Beckmann, M. Marshall, 2012 .

Quantitative detection of platelet GPIIb‐IIIa receptor antagonist activity using a flow cytometric method

L. Green, J. A. Jakubowski, S. Um, 1998, Journal of clinical laboratory analysis.

Prognostic and predictive value of circulating tumor cells and CXCR 4 expression as biomarkers for a CXCR 4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer : exploratory analysis of a phase II study

R. Salgia, M. Connelly, D. Spigel, 2017 .

New insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated)

J. Planquois, G. Sandusky, Mark D. Williams, 2005, Critical care.

Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors

D. Timm, R. Walgren, P. Ebert, 2018, Oncotarget.

Quantitative detection of platelet GPIIb‐IIIa receptor antagonist activity using a flow cytometric method

L. Green, J. Jakubowski, S. Um, 1998, Journal of clinical laboratory analysis.

Dihydroisoquinolone RGD mimics. Exploration of the aspartate isostere

M. J. Fisher, B. Gunn, J. A. Jakubowski, 1997 .

Fused bicyclic Gly-Asp beta-turn mimics with potent affinity for GPIIb-IIIa. Exploration of the arginine isostere.

M. J. Fisher, T. Lindstrom, J. Morin, 2000, Bioorganic & medicinal chemistry letters.

Fused Bicyclic Gly-Asp β-Turn Mimics with Specific Affinity for GPIIb-IIIa

M. J. Fisher, T. Lindstrom, M. Martinelli, 1999 .

Non-peptide RGD surrogates which mimic a Gly-Asp beta-turn: potent antagonists of platelet glycoprotein IIb-IIIa.

M. J. Fisher, B. Gunn, J. A. Jakubowski, 1997, Journal of medicinal chemistry.

Human group II 14 kDa phospholipase A2 activates human platelets.

R. Kramer, J. Jakubowski, K. Clemetson, 1997, The Biochemical journal.

Effect of recombinant human activated protein C on the bactericidal activity of human monocytes and modulation of pro-inflammatory cytokines in the presence of antimicrobial agents.

L. Bopp, A. Baltch, P. Michelsen, 2007, The Journal of antimicrobial chemotherapy.

Use of conformationally restricted benzamidines as arginine surrogates in the design of platelet GPIIb-IIIa receptor antagonists.

J. Wikel, J. Morin, J. Mccowan, 1997, Journal of medicinal chemistry.

Coagulopathy after successful cardiopulmonary resuscitation following cardiac arrest: implication of the protein C anticoagulant pathway.

J. Dhainaut, A. Cariou, C. Adrie, 2005, Journal of the American College of Cardiology.

Phenothiazines as lipid peroxidation inhibitors and cytoprotective agents.

J. Mccowan, S. Um, P. Ho, 1992, Journal of medicinal chemistry.

Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569]

Alain Cariou, James A Russell, J. Dhainaut, 2004, Critical care.

An acyliminium ion approach towards the synthesis of β-substituted 3,4-dihydroisoquinolone propionates

M. J. Fisher, B. Gunn, J. A. Jakubowski, 1997 .

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models

J. Graff, R. Walgren, C. Shih, 2012, Investigational New Drugs.

Platelet glycoprotein IIb–IIIa receptor (GPIIb–IIIa) antagonists derived from amidinoindoles

D. R. Berry, J. Mccowan, J. A. Jakubowski, 1996 .

Circulating endothelial and endothelial progenitor cells in patients with severe sepsis.

L. O'Brien, Mark D. Williams, A. Waxman, 2011, Microvascular research.

Effect of drotrecogin alfa (activated) on human endothelial cell permeability and Rho kinase signaling

C. Vlahos, W. Matter, Wei Zeng, 2004, Critical care medicine.

p38 Mitogen-activated Protein Kinase Phosphorylates Cytosolic Phospholipase A2 (cPLA2) in Thrombin-stimulated Platelets

M. J. Fisher, S. Watson, R. Kramer, 1996, The Journal of Biological Chemistry.

MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping

R. Walgren, J. Manro, V. Wacheck, 2017, Investigational New Drugs.

Systemic host inflammatory and coagulation response in the Dengue virus primo-infection.

S. Um, S. Yan, M. Avila-Aguero, 2004, Cytokine.

Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study

Sameera R. Wijayawardana, Ravi Salgia, R. Salgia, 2017, Investigational New Drugs.

Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569]

J. Dhainaut, A. Cariou, P. Laterre, 2004, Critical care.